Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics的主要癌症藥物與默沙東的暢銷藥物聯合使用，在尿路上皮癌患者中顯示出60%的總體反應率。
On Thursday, Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium.
在週四，Bicycle Therapeutics plc（納斯達克：BCYC）宣佈在2024年聖安東尼奧乳腺會議研討會上展示了zelenectide pevedotin單藥治療在NECTIN4基因擴增的乳腺癌患者中增強的抗腫瘤活性數據。
The company revealed topline combination data for zelenectide pevedotin plus Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC).
該公司公佈了zelenectide pevedotin與默沙東（紐交所：MRK）公司的Keytruda（pembrolizumab）聯合治療在先前未治療（一線）不適合使用順鉑的轉移性尿路上皮癌（mUC）患者中的頂線組合數據。
Topline results from the ongoing Phase 1/2 Duravelo-1 trial evaluating zelenectide pevedotin weekly plus pembrolizumab once every three weeks showed:
正在進行的Duravelo-1一期/二期試驗評估每週使用zelenectide pevedotin加每三週一次的pembrolizumab的頂線結果顯示：
60% overall response rate (ORR) (12/20) among efficacy-evaluable patients. Of the responses, five were...
在有效性可評估的患者中，總...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。